北京商报讯（记者 丁宁）8月19日晚间，健民集团（600976）披露2025年半年报显示，公司上半年实现 的营业收入为18.05亿元，同比下降10.2%；归属净利润为2.21亿元，同比下降7.83%。 健民集团表示，本期营业收入同比下降10.2%，其中医药工业收入增长23.07%，医药商业收入下降 37.82%。医药商业收入下降主要是公司持续优化下属商业子公司业务结构，逐步收缩了部分低毛低效 的业务，导致医药商业板块业务收入有所下降，但公司医药商业板块加大创新性业务如医院SPD业务等 的拓展，业务结构得到持续优化。医药商业板块对公司利润贡献有限，收入的下降对利润的影响不大。 ...

（文章来源：每日经济新闻） 每经AI快讯，8月19日，健民集团公告称，公司发布2025年半年度报告，公司营业收入和净利润均出现 下降。营业收入为18.05亿元，同比下降10.2%；净利润为2.21亿元，同比下降7.83%。主要原因是联营 企业投资收益及非经常性损益减少。 ...

格隆汇8月19日丨健民集团(600976.SH)公布2025年半年度报告，报告期实现营业收入18.05亿元，同比下 降10.20%；归属于上市公司股东的净利润2.21亿元，同比下降7.83%；归属于上市公司股东的扣除非经 常性损益的净利润1.95亿元，同比增长0.61%；基本每股收益1.46元。 ...

健民集团公告，2025年上半年营业收入18.05亿元，同比下降10.20%。净利润2.21亿元，同比下降 7.83%。 ...

Group 1 - The company has received the clinical trial approval notice for the nasal congestion granules from the National Medical Products Administration [1] - The nasal congestion granules are indicated for the treatment of acute sinusitis and have shown good efficacy and safety in clinical applications [1][2] - The market for nasal medication is significant, with 26% of the adult population in China suffering from nasal inflammation or sinusitis, and the market demand for nasal medication is expected to grow [2] Group 2 - The sales revenue for nasal medication (traditional Chinese medicine) is projected to be 2.757 billion yuan in 2023 and 3.061 billion yuan in 2024, with the nasal congestion granules expected to generate sales of 409 million yuan in 2023 and 475 million yuan in 2024 [2] - There are several traditional Chinese medicine products approved for the treatment of acute sinusitis, including nasal congestion granules, with one approval number for the nasal congestion granules [3] - The company must complete clinical trials and submit a marketing authorization application to the National Medical Products Administration before the product can be marketed [4]

Core Viewpoint - Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating progress in its product development pipeline [2] Company Summary - Jianmin Group announced on August 14 that it has obtained the clinical trial approval from the National Medical Products Administration for its nasal medication, Nasal Congestion Relief Granules [2]

Group 1 - The core point of the article is that Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating a significant development in its product pipeline [2] - Jianmin Group's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 49.83%, pharmaceutical commerce for 49.56%, and other businesses for 0.6% [2]

证券简称：健民集团 证券代码：600976 公告编号：2025-031 健民药业集团股份有限公司 关于获得《药物临床试验批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的鼻渊通窍颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第3号——行业信息披露》的相关要求，现将有关情况公告 如下： | 药品名称 | 鼻渊通窍颗粒 | 申请人 | 健民药业集团股份有限公司 | | --- | --- | --- | --- | | 注册分类 | 中药4类 | 剂型 | 颗粒剂 | | 通知书编号 | 2025LP02040 | 受理号 | CYZL2500001 | | 适应症 | 急性鼻窦炎 | | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，鼻渊通窍颗粒临床试 | | | | | 验申请符合药品注册的有关要求，同意本品开展用于急性鼻窦炎的临床 | | | | | 试验。 | | | 二、药 ...

Core Viewpoint - Jianmin Group (600976.SH) has received the Clinical Trial Approval Notice for the nasal medication "Biyuan Tongqiao Granules" from the National Medical Products Administration, indicating a significant step in the development of this traditional Chinese medicine [1] Group 1 - The product "Biyuan Tongqiao Granules" is a traditional Chinese medicine that has already been marketed [1] - The primary function of the granules is to dispel wind and clear heat, as well as to promote lung function and open nasal passages [1] - The medication is indicated for acute nasal inflammation (acute sinusitis) associated with external pathogens affecting the lungs, with symptoms including pressure pain in the forehead or cheekbones, nasal congestion, and other related symptoms [1]

Core Viewpoint - The company, Jianmin Group, has received approval from the National Medical Products Administration for clinical trials of its nasal medication, indicating a significant step in the development of a treatment for acute sinusitis [1] Company Summary - Jianmin Group (stock code: 600976) announced on August 14 that it has obtained the "Drug Clinical Trial Approval Notice" for its product, Nasal Congestion Relief Granules [1] - The approved indication for this medication is acute sinusitis, which suggests potential market opportunities in addressing this common health issue [1]